Director and 10% Owner Gregg Williams Buys Nearly $2 Million in Vivani Medical Stock
VANI sits 32% above its 52-week low of $0.923.
Summary
A Director and 10% owner of Vivani Medical purchased nearly $2 million worth of company stock, indicating strong insider confidence.
Key Events · Ownership and Investor Activity · VANI
-
Significant Insider Purchase
Gregg Williams, a Director and 10% owner, acquired 1,587,301 shares for $1,999,999.26 in an open market transaction on April 15, 2026.
-
Strong Conviction Signal
This purchase represents over 2% of the company's market capitalization, indicating high confidence from a key insider.
-
Follows Recent Capital Raise
This investment follows the company's successful capital raise and advancement of its lead semaglutide implant into Phase 1, as noted in the recent 10-K.
Analysis · VANI · Industrial Applications And Services
Gregg Williams, a Director and 10% owner of Vivani Medical, made a substantial open-market purchase of nearly $2 million in company stock. This significant investment, representing over 2% of the company's market capitalization, signals strong conviction in the company's future prospects. This follows the company's recent successful capital raise and advancement of its lead semaglutide implant into Phase 1, as reported in the last 10-K. Such a large insider buy, especially from a director with significant ownership, can be interpreted as a highly positive signal to the market.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 40.7% of the 388 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.42%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VANI was trading at $1.22 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $96.5M. The 52-week trading range was $0.92 to $1.92. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.